Journal of Nuclear Medicine: 64 (9)

September 1, 2023; Volume 64,Issue 9

Cover image

FEATURED ARTICLE

Human Epidermal Growth Factor Receptor 2-Targeting [⁶⁸Ga]Ga-ABY-025 PET/CT Predicts Early Metabolic Response in Metastatic Breast Cancer. Ali Alhuseinalkhudhur et al. See page 1364.

In this issue

Issue highlights

Human Epidermal Growth Factor Receptor 2–Targeting [⁶⁸Ga]Ga-ABY-025 PET/CT Predicts Early Metabolic Response in Metastatic Breast Cancer
Preclinical Characterization of the Tau PET Tracer [¹⁸F]SNFT-1: Comparison of Tau PET Tracers

Initial Clinical Experience with ⁹⁰Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients
Total-Body PET Multiparametric Imaging of Cancer Using a Voxelwise Strategy of Compartmental Modeling
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with ¹⁷⁷Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial
⁶⁸Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the ⁶⁸Ga-FAPI PET Prospective Observational Trial

More...

Main menu

User menu

Search

Table of Contents

Cover image

In this issue

Issue highlights

Jump to